{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:37Z","timestamp":1792449577559,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["IGA_PrF_2025_011"],"award-info":[{"award-number":["IGA_PrF_2025_011"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118309","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:07:31Z","timestamp":1761782851000},"page":"118309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia"],"prefix":"10.1016","volume":"302","author":[{"given":"Neetu","family":"Dayal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"\u0158ezn\u00ed\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delmis E.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Pe\u0159ina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"B\u011bl\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Voj\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kr\u0148\u00e1vkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ba\u0159ina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas R.","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Kaur","family":"Hunjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-7126","authenticated-orcid":false,"given":"Radek","family":"Jorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-9359","authenticated-orcid":false,"given":"Herman O.","family":"Sintim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118309_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-Approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118309_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118309_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4155\/fmc-2017-0298","article-title":"Dual FLT3\/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines","volume":"10","author":"Dayal","year":"2018","journal-title":"Future Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2025.118309_bib8","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1021\/acs.jmedchem.1c00330","article-title":"3H-Pyrazolo[4,3-f]quinoline-based kinase inhibitors inhibit the proliferation of acute myeloid leukemia cells in vivo","volume":"64","author":"Dayal","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118309_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118309_bib15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. Cancer Genome Atlas Research Network","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118309_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118309_bib1","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118309_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118309_bib14","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ejmech.2025.118309_bib18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118309_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118309_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118309_bib4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118309_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118309_bib23","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118309_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118309_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098800","article-title":"A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination","volume":"9","author":"Rudolf","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118309_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.chembiol.2017.10.010","article-title":"Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement","volume":"25","author":"Vasta","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118309_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118309_bib9","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/acs.jmedchem.7b01529","article-title":"Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations","volume":"61","author":"Guck\u00fd","year":"2018","journal-title":"J. Med. Chem."},{"issue":"36","key":"10.1016\/j.ejmech.2025.118309_bib17","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1039\/C8CC01154K","article-title":"Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor","volume":"54","author":"Opoku-Temeng","year":"2018","journal-title":"Chem Commun (Camb"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118309_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118309_bib29","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"issue":"7511","key":"10.1016\/j.ejmech.2025.118309_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118309_bib27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118309_bib2","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1021\/acs.jmedchem.3c00575","article-title":"Inhibition of FLT3-ITD kinase in acute myeloid leukemia by new Imidazo[1,2-b]pyridazine derivatives identified by scaffold hopping","volume":"66","author":"B\u0159ehov\u00e1","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118309_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"Avogadro: an advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminf."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118309_bib11","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/acs.jcim.0c00165","article-title":"Assessment of binding affinity via alchemical free-energy calculations","volume":"60","author":"Kuhn","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118309_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:02:22Z","timestamp":1780909342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0223523425010748"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118309","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118309"}}